KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with observations from 100 patients treated with KYV-101 to date1 Emerging IIT data in RA reinforce broad potential for KYV-101 in rheumatology indications Oct. 25, 2025 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical compan

Oct. 21, 2025 -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the Journal of Clinical Oncology (JCO). The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind,

Oct. 22, 2025 -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu Lab. Existing investors, Brandon Capital, Uniseed and Stoic Venture Capital also participated in the round. The new f

Oct. 23, 2025 -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 21,023,337 shares of its common stock and pre-funded warrants to purchase up to 3,226,458 shares of its common stock (the “Offering”). The offering price of each share of common stock is $8.66. The offering price of each pre-funded warrant is $8.659, w

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially s

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%. Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. Oct. 23, 2025 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofron

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; safety profile consistent with known profile of Cosentyx1 Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥502, with limited options available October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab

Approval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change from baseline in Forced Vital Capacity at 52 weeks with nerandomilast 18 mg and 9 mg versus placebo in adults with idiopathic pulmonary fibrosis (IPF)1,2 Nerandomilast was included in the priority review by the Centre for Drug Evaluation (CDE) of the NMPA in January this year, and was recently granted FDA approval in the United States. Boehringer Ingelheim

Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and well-tolerated, with no increase in serious adverse events versus placebo. Scp776 leverages Silver Creek’s proprietary Smart Growth Factor™ platform to selectively deliver a growth factor (IGF-1) to injured cells, representing a novel targeted biologic approach to stroke therapy. Oct. 23, 2025 --

Oct. 22, 2025 -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. This milestone marks a crucial turning point as ProPhase moves from validation